Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

RUTF potenziata dalla membrana del globulo grasso di latte per bambini con grave malnutrizione acuta (MEND-SAM)

1 novembre 2026 aggiornato da: Washington University School of Medicine

RUTF potenziato da MFGM per bambini con SAM

The goal of this clinical trial is to test the use of milk fat globule membrane (MFGM) in ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition in Sierra Leone. The main questions it aims to answer are:

  • Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition improve their neurodevelopment?
  • Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition reduce its worst consequences: death, hospitalization, and remaining severely malnourished despite treatment?

Researchers will compare the MFGM-containing RUTF to standard RUTF, which contains skim milk powder.

Participants will:

  • undergo measurement of length, weight, mid-upper arm circumference, and nutritional edema assessment every two weeks during severe malnutrition treatment
  • be treated with either MFGM-RUTF or standard RUTF at a dose of 2 sachets per day for up to 12 weeks
  • undergo neurodevelopmental testing using the Malawi Developmental Assessment Tool at the end of SAM treatment and 6 months later
  • a subset of participants will undergo blood spot collection and stool sample collection

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Globally, approximately 15 million children are suffering from severe acute malnutrition (SAM) at any one time, a number that has not declined in recent decades despite significant technological advancements in agriculture and food science. SAM is a condition of total-body depletion of the nutrients required for health and development; without treatment, 50% of affected children will die. Whereas historically children with SAM were admitted to and treated within hospitals, the advent of ready-to-use therapeutic food (RUTF) and community-based management of acute malnutrition revolutionized SAM care by allowing it to occur safely and successfully by the child's caregiver in their own home.

RUTF was designed to provide the nutrients required for physical recovery in a safe, palatable format. It is equal parts peanut paste, sugar, vegetable oil, and skim milk powder, with added micronutrients and emulsifier. At inception, attention was not specifically paid to how RUTF's composition might impact neurodevelopmental recovery in children with SAM. Research over the past decade has revealed that even following successful treatment with RUTF, children diagnosed with SAM still score 1-3 standard deviations below age-based expectations on neurodevelopmental tests. This suggests that the nutrient profile of standard RUTF is not sufficient to recover the developmental damage incurred by SAM.

Recently, progress has been made toward improving the developmental trajectory of children with SAM by altering RUTF. A randomized, blinded trial in Malawi including 2,500 children with SAM showed that improving the polyunsaturated fatty acid (PUFA) profile of RUTF by reducing linoleic acid and adding docosahexaenoic acid (DHA) yields superior neurodevelopment 6 months after treatment, by 0.19 standard deviations on a standardized, culturally adapted neurodevelopmental test. This demonstrates that neurodevelopmental recovery in SAM is sensitive to the lipid profile of RUTF. Despite the benefits of improved PUFA RUTF, however, children with SAM remained 1 standard deviation below expectations in neurodevelopment.

The milk fat globule membrane (MFGM) in mammalian milk contains a host of nutrients and bioactive compounds supportive of physical health and brain development. Bovine MFGM added to infant formula has been tested in several clinical trials and has demonstrated a reduction in infectious episodes, such as diarrhea and ear infections, as well as improvement in cognitive development, compared with infant formula not containing MFGM. In these trials and others, MFGM has been shown to be safe and well-tolerated. Currently, RUTF contains skim milk powder as its high-quality protein source, and peanut and vegetable oils as the primary sources of fat. These vegetable fat sources are deficient in the lipids provided by MFGM: sphingolipids, cholesterol, and other phospholipids such as phosphatidylcholine and phosphatidylethanolamine, all of which play roles in brain development. It is possible that the lipids contained in MFGM may further support neurodevelopmental recovery in SAM children.

By acting as a natural emulsifier, MFGM also offers a food formulation advantage that is relevant to children with SAM. Animal model studies have demonstrated that emulsifiers can compromise the gut barrier. Children with SAM have damaged small intestinal barrier function, which can lead to translocation of gut bacteria and resulting systemic infection. As RUTF will compose nearly 100% of a child's intake for the duration of treatment - up to 3 months - it is possible that inclusion of emulsifier may impede gut healing and recovery. Considering this concern, the Manary lab ran a clinical trial in 2018-2019 testing a novel formulation of RUTF designed with oat in place of some skim milk powder and peanut, and without hydrogenated vegetable oil (standard emulsifier), because oat acts as a natural emulsifier. In this trial, children with SAM receiving the oat-RUTF had 10% absolute higher recovery and a 33% relative reduction in the worst SAM outcomes (death, hospitalization, or remaining severely malnourished). Like oat, MFGM in RUTF allows for omission of emulsifier and may yield similar benefits.

Given (1) the repeated finding that adding MFGM to infant formulas improves neurodevelopment, (2) the impaired neurodevelopment of children with SAM, (3) the current RUTF formulation lacking neuro-supportive fats provided by MFGM, (4) MFGM's natural activity as an emulsifier, and (5), the reality that RUTF provides the sole source of nutrition for children with SAM, it is plausible that adding this high-quality source of lipids and protein to RUTF may also benefit children with SAM in both immediate and long-term physical and cognitive recovery.

This will be an individually randomized, investigator/outcomes assessors-blinded, controlled clinical trial designed to determine if treatment of severely malnourished Sierra Leonean children 6-59-months of age with an RUTF made with MFGM-containing whey protein/fat concentrate will (1) improve neurodevelopment and (2) reduce a composite of poor SAM outcomes (death, hospitalization, remaining severely malnourished), compared with standard RUTF (S-RUTF). This trial will be conducted at 20 rural sites in Sierra Leone. 1600 children will be randomized 1:1 to receive 2 sachets per day of either MFGM-RUTF or S-RUTF. Children will receive their allocated RUTF and return to clinic fortnightly for repeat anthropometric measurements, illness questions, and to receive more RUTF until they achieve a clinical outcome or for a maximum of 12 weeks, at which point they will undergo Malawi Developmental Assessment Tool (MDAT) testing. Participants will be asked to return to clinic 6 (5-7) months later for MDAT testing, the global z-score from which will be the trial's co-primary outcome. A subset of participants will undergo blood spot and/or stool sample collection at the end of SAM treatment.

Tipo di studio

Interventistico

Iscrizione (Stimato)

1600

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Pujehun
      • Bandajuma, Pujehun, Sierra Leone
        • Bandajuma
      • Bandasuma, Pujehun, Sierra Leone
        • Bandasuma
      • Bendu Malen, Pujehun, Sierra Leone
        • Bendu Malen
      • Gbondapi, Pujehun, Sierra Leone
        • Gbondapi
      • Jendema, Pujehun, Sierra Leone
        • Jendema
      • Potoru, Pujehun, Sierra Leone
        • Potoru
      • Pujehun, Pujehun, Sierra Leone
        • Static
      • Sahn Malen, Pujehun, Sierra Leone
        • Sahn Malen
      • Taninahun, Pujehun, Sierra Leone
        • Taninahun
      • Zimmi, Pujehun, Sierra Leone
        • Zimmi

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 6 mesi a 4 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 6-59 months of age
  • Reside within the catchment area of a participating clinic
  • mid-upper arm circumference < 11.5 cm and/or weight-for-length z-score < -3 and/or presence of bilateral pedal pitting edema
  • willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic

Exclusion Criteria:

  • Features of complicated SAM: inability to tolerate a 30 g test dose of RUTF, breathing difficulties, mental status changes, sepsis, diarrhea with severe dehydration, and/or physician/nursing clinical assessment that the child needs immediate hospitalization
  • Participation in a separate therapeutic feeding program within the past month
  • Known allergy to study food ingredient (peanut, milk, fish)
  • Clinically evident developmental delay (most often determined based on research nursing assessment of physical appearance, movement, and informal discussion with caregiver)
  • Presence of a chronic severe medical condition (other than tuberculosis and HIV), such as congenital heart disease

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: MFGM-RUTF (Milk fat globule membrane ready-to-use therapeutic food)

One sachet contains 92g of MFGM-RUTF. During SAM treatment, each participant will be given sufficient MFGM-RUTF to consume 2 sachets per day, which will provide approximately 1000 calories, 27g of protein, 63g of fat, and over 1 RDA of micronutrients.

MFGM whey protein/fat concentrate powder used in place of skim milk powder in peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications. There will be 10g of MFGM-containing whey protein/fat concentrate powder per 100g of MFGM-RUTF. Other ingredients and amounts per 100g: 9.5g rice flour, 5g whey permeate, 18.5g palm oil, 31g peanut paste, 22.1g sugar, 2.9g micronutrient mix, 1g fish oil.

Oral amoxicillin tablets twice per day for 7 days dosed based on weight

Malaria chemoprophylaxis, dosed by weight, to be given every month during SAM treatment

Comparatore attivo: S-RUTF (standard ready-to-use therapeutic food)

One sachet contains 92g of S-RUTF. During SAM treatment, each participant will be given sufficient S-RUTF to consume 2 sachets per day, which will provide approximately 1000 calories, 27g of protein, 60g of fat, and over 1 RDA of micronutrients.

Oral amoxicillin tablets twice per day for 7 days dosed based on weight

Malaria chemoprophylaxis, dosed by weight, to be given every month during SAM treatment

Standard peanut paste-based ready-to-use therapeutic food made with skim milk powder meeting Codex Alimentarius specifications. This RUTF is modeled on the most widely used recipe worldwide, containing per 100g: 19.5g skim milk powder, 9.3g palm oil, 7g canola oil, 31.3g peanut paste, 28g sugar, 1g soy flakes, 1g hydrogenated vegetable oil, and 2.9g micronutrient mix.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Malawi Developmental Assessment Tool global z-score
Lasso di tempo: 6 (5-7) months after SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

6 (5-7) months after SAM treatment completion
Composite of poor severe acute malnutrition treatment outcomes
Lasso di tempo: 2-12 weeks of therapeutic feeding

This composite outcome will include death, hospitalization, and remaining severely malnourished despite 12 weeks of treatment

2-12 weeks of therapeutic feeding

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Malawi Developmental Assessment Tool gross motor domain z-score
Lasso di tempo: 6 (5-7) months after SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

6 (5-7) months after SAM treatment completion
Malawi Developmental Assessment Tool fine motor domain z-score
Lasso di tempo: 6 (5-7) months after SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

6 (5-7) months after SAM treatment completion
Malawi Developmental Assessment Tool language domain z-score
Lasso di tempo: 6 (5-7) months after SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

6 (5-7) months after SAM treatment completion
Malawi Developmental Assessment Tool social-emotional domain z-score
Lasso di tempo: 6 (5-7) months after SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

6 (5-7) months after SAM treatment completion
Remaining severely malnourished at end of SAM treatment
Lasso di tempo: 12 weeks of therapeutic feeding

For MUAC enrollment: MUAC < 11.5 cm For WLZ enrollment: WLZ < -3 For enrollment by both MUAC and WLZ: either remaining in SAM range For nutritional edema enrollment: continued edema

12 weeks of therapeutic feeding
Death during SAM treatment
Lasso di tempo: 2-12 weeks of therapeutic feeding

As per caregiver/family report

2-12 weeks of therapeutic feeding
Hospitalization during SAM treatment
Lasso di tempo: 2-12 weeks of therapeutic feeding

Participant determined to require hospitalization. Determination may be made by caregiver/family, government health workers, or may be recommended by trial staff for clinical decompensation.

2-12 weeks of therapeutic feeding
Graduation from SAM treatment
Lasso di tempo: 2-12 weeks of therapeutic feeding

For MUAC enrollment: MUAC ≥ 12.5cm For WLZ enrollment: WLZ > -2 based on enrollment length For MUAC and WLZ enrollment: may meet either For edema enrollment: resolution of edema, with at least 4 weeks treatment

2-12 weeks of therapeutic feeding
Malawi Developmental Assessment Tool global z-score
Lasso di tempo: Within 1 month of SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

Within 1 month of SAM treatment completion
Malawi Developmental Assessment Tool gross motor domain z-score
Lasso di tempo: Within 1 month of SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

Within 1 month of SAM treatment completion
Malawi Developmental Assessment Tool fine motor domain z-score
Lasso di tempo: Within 1 month of SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

Within 1 month of SAM treatment completion
Malawi Developmental Assessment Tool language domain z-score
Lasso di tempo: Within 1 month of SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

Within 1 month of SAM treatment completion
Malawi Developmental Assessment Tool social-emotional domain z-score
Lasso di tempo: Within 1 month of SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better

Within 1 month of SAM treatment completion
Rate of weight change
Lasso di tempo: Across initial 4 weeks of therapeutic feeding, or 2 weeks if graduate after 2 weeks

g / kg / day

Across initial 4 weeks of therapeutic feeding, or 2 weeks if graduate after 2 weeks
Rate of length change
Lasso di tempo: Across 2-12 weeks of therapeutic feeding

mm / week

Across 2-12 weeks of therapeutic feeding
Rate of mid-upper arm circumference change
Lasso di tempo: Across 2-12 weeks of therapeutic feeding

mm / week

Across 2-12 weeks of therapeutic feeding
Rate of change in length-for-age z-score across entire follow-up
Lasso di tempo: 7-10 months (2-12 weeks of therapeutic feeding, 5-7 months of follow-up thereafter)

Difference in LAZ at final visit and initial visit divided by time months transpired

7-10 months (2-12 weeks of therapeutic feeding, 5-7 months of follow-up thereafter)
Diarrhea incidence during SAM treatment
Lasso di tempo: 2-12 weeks of therapeutic feeding

Caregiver report of participant diarrhea (>2 loose stools per day) during SAM treatment

2-12 weeks of therapeutic feeding
Fever incidence during SAM treatment
Lasso di tempo: 2-12 weeks of therapeutic feeding

Caregiver report of participant fever during SAM treatment

2-12 weeks of therapeutic feeding
Plasma DHA status at end of SAM treatment
Lasso di tempo: Collected after 2-12 weeks of therapeutic feeding

Blood spot DHA % total fatty acids in subset of participants at end of therapeutic feeding

Collected after 2-12 weeks of therapeutic feeding
Fecal host mRNA transcripts as markers of environmental enteric dysfunction at end of SAM treatment
Lasso di tempo: Collected after 2-12 weeks of therapeutic feeding

CD53, CDX1, HLA-DRA, TNF, S100A8, MUC12, and REG1A

Collected after 2-12 weeks of therapeutic feeding
Malawi Developmental Assessment Tool global z-score trajectory
Lasso di tempo: 6 (5-7) months after SAM treatment completion

Change in MDAT global z-score between initial test and final test

6 (5-7) months after SAM treatment completion

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Malawi Developmental Assessment Tool global z-score in sub-groups
Lasso di tempo: 6 (5-7) months after SAM outcome

Age-standardized score, -6 to +6, higher scores are better. Will be tested in subgroups based on SAM treatment outcome (graduation vs. other), age at enrollment, and sex

6 (5-7) months after SAM outcome
Malawi Developmental Assessment Tool global z-score in sub-groups
Lasso di tempo: Within 1 month of SAM treatment completion

Age-standardized score, -6 to +6, higher scores are better. Will be tested in subgroups based on SAM treatment outcome (graduation vs. other), age at enrollment, and sex

Within 1 month of SAM treatment completion
Composite of poor severe acute malnutrition treatment outcomes
Lasso di tempo: 2-12 weeks of therapeutic feeding

This composite outcome will include death, hospitalization, and remaining severely malnourished despite 12 weeks of treatment. This will be tested in subgroups by age at enrollment, sex, and enrollment criteria.

2-12 weeks of therapeutic feeding

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Mark J Manary, MD, Washington University School of Medicine
  • Investigatore principale: Kevin B Stephenson, MD, Washington University School of Medicine
  • Direttore dello studio: Indi Trehan, MD, MPH, University of Washington

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 settembre 2025

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

5 marzo 2025

Primo inviato che soddisfa i criteri di controllo qualità

5 marzo 2025

Primo Inserito (Effettivo)

11 marzo 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Periodo di condivisione IPD

Within 12 months of primary publication

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .